Press release Ecully, November 7, 2016
Approval of a €1.4M capital increase
by a General Meeting of Spineway's shareholders
Spineway , company specialized in surgical implants and instruments for the treatment of disorders of the spinal column, held an Extraordinary General Shareholders' Meeting on November 4, 2016, at Spineway's registered office in Ecully, chaired by Stéphane Le Roux, the Group's President.
The Shareholders' Meeting approved all of the resolutions submitted, including, in particular, the reserved capital increase by issuing ABSAs (shares with warrants attached) without preferential subscription rights, representing an amount of EUR 1,399,724.40 (including issue premium).
This capital increase, fully subscribed by the Chinese company TINAVI Medical Technologies, should be finalized before the end of November 2016.
All of the resolutions submitted and voted on can be found on www.spineway.com
SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLAN FOR SMES)
Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its turnover comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), received the OSEO Excellence award as well as the Deloitte Fast 50 award in 2011. Rhône Alpes INPI Patent Innovation Award (2013) -Talent INPI award (2015).
David Siegrist - Chief Financial Officer
Tel : +33 (0)4 72 77 01 52
Jérôme Gacoin / Solène Kennis
Tel: +33 (0)1 75 77 54 68
Last updated on: 09/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.